TXLNA

Summary

TXLNA (taxilin alpha, HGNC:30685) is a protein-coding gene on chromosome 1p35.2, encoding Alpha-taxilin (P40222). May be involved in intracellular vesicle traffic and potentially in calcium-dependent exocytosis in neuroendocrine cells.

Predicted to enable syntaxin binding activity. Predicted to be involved in exocytosis. Predicted to act upstream of or within B cell activation. Located in cytoplasm.

Source: NCBI Gene 200081 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 86 total
• Druggable target: yes
• MANE Select transcript: NM_175852

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30685
Approved symbol	TXLNA
Name	taxilin alpha
Location	1p35.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp451J0118, IL-14, IL14
Ensembl gene	ENSG00000084652
Ensembl biotype	protein_coding
OMIM	608676
Entrez	200081

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 15 protein_coding

ENST00000373609, ENST00000373610, ENST00000867264, ENST00000867265, ENST00000867266, ENST00000867267, ENST00000867268, ENST00000867269, ENST00000867270, ENST00000867271, ENST00000932072, ENST00000932073, ENST00000932074, ENST00000962758, ENST00000962759

RefSeq mRNA: 4 — MANE Select: NM_175852 NM_001376857, NM_001376858, NM_001376859, NM_175852

CCDS: CCDS353

Canonical transcript exons

ENST00000373610 — 11 exons

Exon	Start	End
ENSE00000542105	32192657	32192731
ENSE00000763548	32193208	32193300
ENSE00000763570	32194065	32194160
ENSE00000825430	32187954	32188124
ENSE00001170250	32190055	32190249
ENSE00001170262	32184525	32184616
ENSE00001170269	32181242	32181577
ENSE00001246056	32179675	32179776
ENSE00001461022	32194902	32198285
ENSE00001664733	32192311	32192430
ENSE00002051326	32180314	32180514

Expression profiles

Bgee: expression breadth ubiquitous, 266 present calls, max score 92.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 57.9913 / max 4234.9505, expressed in 1824 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1954	19.8219	1773
1949	17.0464	1800
1951	15.8688	1806
1948	3.6028	1640
1950	1.1670	817
1952	0.4844	241

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	92.57	gold quality
tendon of biceps brachii	UBERON:0008188	92.11	gold quality
right adrenal gland	UBERON:0001233	91.67	gold quality
left adrenal gland	UBERON:0001234	91.57	gold quality
right adrenal gland cortex	UBERON:0035827	91.52	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.43	gold quality
lower esophagus	UBERON:0013473	91.41	gold quality
body of uterus	UBERON:0009853	91.36	gold quality
left adrenal gland cortex	UBERON:0035825	91.32	gold quality
right coronary artery	UBERON:0001625	91.25	gold quality
left uterine tube	UBERON:0001303	91.14	gold quality
adenohypophysis	UBERON:0002196	90.95	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.80	gold quality
right lobe of liver	UBERON:0001114	90.78	gold quality
islet of Langerhans	UBERON:0000006	90.77	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.75	gold quality
adrenal gland	UBERON:0002369	90.72	gold quality
adrenal cortex	UBERON:0001235	90.71	gold quality
descending thoracic aorta	UBERON:0002345	90.69	gold quality
thoracic aorta	UBERON:0001515	90.57	gold quality
ascending aorta	UBERON:0001496	90.52	gold quality
esophagus	UBERON:0001043	89.96	gold quality
pituitary gland	UBERON:0000007	89.87	gold quality
aorta	UBERON:0000947	89.82	gold quality
right lobe of thyroid gland	UBERON:0001119	89.82	gold quality
right ovary	UBERON:0002118	89.71	gold quality
endocervix	UBERON:0000458	89.59	gold quality
apex of heart	UBERON:0002098	89.39	gold quality
mucosa of transverse colon	UBERON:0004991	89.36	gold quality
popliteal artery	UBERON:0002250	89.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

177 targeting TXLNA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-570-3P	99.96	72.41	4910
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-6721-5P	99.93	68.92	2981

Literature-anchored findings (GeneRIF, showing 14)

• identification of isoforms; interaction with syntaxin [alpha-taxilin] (PMID:15184072)
• role for IL-14alpha (Txln gene product)in the development of both autoimmunity and lymphomagenesis (PMID:17015757)
• increases in IL-14 transcript levels may play a role in alloantibody formation after renal transplantation (PMID:18645499)
• IL-14a is important in the pathophysiology of Sjogren’s disease (PMID:19038581)
• analysis of a novel monoclonal antibody against interleukin-14alpha (PMID:19663695)
• alpha-taxilin may be involved in cell proliferation of hepatocellular carcinoma(HCC), and its expression can be a marker of malignant potential of HCC. (PMID:21042709)
• Increased alpha-taxilin protein expression is associated with the metastatic and invasive potential of renal cell cancer. (PMID:21551945)
• Alpha-taxilin is localized on intracellular components in a syntaxin-independent manner and that the alpha-taxilin-containing intracellular components are associated with the microtubule cytoskeleton. (PMID:22785156)
• alpha-taxilin plays an essential role for release of HBV-DNA containing particles. (PMID:23816704)
• alpha-taxilin interacts with SNX4 and plays a role in the recycling pathway of TfnR. (PMID:24690921)
• intrathyroidal production of IL-14 and IL-16 associated with the pathogenesis of autoimmune thyroid disease (PMID:25940130)
• Silencing of alpha-taxilin expression leads to increased release of infectious hepatitis C virus particles. (PMID:26527738)
• High TXLNA Expression Predicts Favourable Outcome for Pancreatic Adenocarcinoma Patients. (PMID:32185195)
• alpha-/gamma-Taxilin are required for centriolar subdistal appendage assembly and microtubule organization. (PMID:35119360)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	txlna	ENSDARG00000077037
mus_musculus	Txlna	ENSMUSG00000053841
rattus_norvegicus	Txlna	ENSRNOG00000048242

Paralogs (2): TXLNG (ENSG00000086712), TXLNB (ENSG00000164440)

Protein

Protein identifiers

Alpha-taxilin — P40222 (reviewed: P40222)

All UniProt accessions (1): P40222

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in intracellular vesicle traffic and potentially in calcium-dependent exocytosis in neuroendocrine cells.

Subunit / interactions. Binds to the C-terminal coiled coil region of syntaxin family members STX1A, STX3A and STX4A, but not when these proteins are complexed with SNAP25, VAMP2 or STXBP1, suggesting that it interacts with syntaxins that do not form the SNARE complex.

Tissue specificity. Ubiquitous, with much higher expression in heart, kidney, liver and pancreas.

Similarity. Belongs to the taxilin family.

RefSeq proteins (4): NP_001363786, NP_001363787, NP_001363788, NP_787048* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026183	Taxilin_fam	Family

Pfam: PF09728

UniProt features (18 total): sequence conflict 8, compositionally biased region 4, region of interest 2, modified residue 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P40222-F1	75.29	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 72, 515

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-449836	Other interleukin signaling

MSigDB gene sets: 136 (showing top): REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_B_CELL_ACTIVATION, MORF_HDAC2, GOBP_VESICLE_MEDIATED_TRANSPORT, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_EXOCYTOSIS, BLALOCK_ALZHEIMERS_DISEASE_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, GOBP_SECRETION, MORF_PRKDC, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, MORF_AATF, MORF_ORC1L, BIOCARTA_CYTOKINE_PATHWAY, MARSON_BOUND_BY_E2F4_UNSTIMULATED

GO Biological Process (2): exocytosis (GO:0006887), B cell activation (GO:0042113)

GO Molecular Function (2): syntaxin binding (GO:0019905), protein binding (GO:0005515)

GO Cellular Component (4): extracellular region (GO:0005576), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
lymphocyte activation	1
SNARE binding	1
binding	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

838 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TXLNA	TSG101	Q99816	810
TXLNA	STX4	Q12846	805
TXLNA	STX3	Q13277	795
TXLNA	STX1A	Q16623	699
TXLNA	STX8	Q9UNK0	635
TXLNA	IFNG	P01579	578
TXLNA	IL5	P05113	567
TXLNA	STX7	O15400	549
TXLNA	IL19	Q9UHD0	509
TXLNA	IL13	P35225	506
TXLNA	IL4	P05112	470
TXLNA	IL11	P20809	470
TXLNA	ERVFRD-1	P60508	446
TXLNA	ERV3-1	Q14264	446
TXLNA	IL10	P22301	445

IntAct

528 interactions, top by confidence:

A	B	Type	Score
TXLNB	TXLNA	psi-mi:“MI:0915”(physical association)	0.880
TXLNA	TXLNB	psi-mi:“MI:0915”(physical association)	0.880
HIF1AN	APBA3	psi-mi:“MI:0914”(association)	0.850
MED4	TXLNA	psi-mi:“MI:0915”(physical association)	0.840
TXLNA	MED4	psi-mi:“MI:0915”(physical association)	0.840
NDC80	TXLNA	psi-mi:“MI:0915”(physical association)	0.800
TXLNA	KRT38	psi-mi:“MI:0915”(physical association)	0.800
TXLNA	NDC80	psi-mi:“MI:0915”(physical association)	0.800
CDR2	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
KRT31	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
TXLNA	KRT40	psi-mi:“MI:0915”(physical association)	0.780
TXLNA	VPS52	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
TCL1A	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
BTF3L4	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
GORASP2	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
WASHC3	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
TXLNA	KRT31	psi-mi:“MI:0915”(physical association)	0.780
KRT40	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
VPS52	TXLNA	psi-mi:“MI:0915”(physical association)	0.780

BioGRID (376): TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid), TXLNA (Two-hybrid)

ESM2 similar proteins: A0PJP4, A0PJT0, A2A6T1, A2VDP1, D3YV10, D3ZUQ0, G9G127, O75150, O88448, P40222, P97817, Q08379, Q17QG3, Q2HJJ0, Q3U319, Q4R7K7, Q4V328, Q4V872, Q5DTM8, Q5EBL4, Q5PQM2, Q5RAU7, Q5VTR2, Q5XJA2, Q5ZLS3, Q62036, Q62839, Q6AYA0, Q6DFC2, Q6PAM1, Q6ZUS6, Q80YF0, Q86X02, Q8BR07, Q8C9S4, Q8CG73, Q8CJB9, Q8IYE1, Q8TD16, Q8VD04

Diamond homologs: P40222, Q6GVM5, Q6PAM1, Q8BHN1, Q8N3L3, Q8VBT1, Q9BZA5, Q9I969, Q9NUQ3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	9	19.8×	8e-08
Loss of proteins required for interphase microtubule organization from the centrosome	9	19.8×	8e-08
AURKA Activation by TPX2	9	19.0×	9e-08
Anchoring of the basal body to the plasma membrane	12	18.8×	5e-10
Recruitment of mitotic centrosome proteins and complexes	9	17.0×	2e-07
Regulation of PLK1 Activity at G2/M Transition	9	15.9×	3e-07
Recruitment of NuMA to mitotic centrosomes	9	14.6×	6e-07
Formation of the cornified envelope	6	7.3×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
centriole replication	5	37.8×	1e-04
morphogenesis of an epithelium	6	21.3×	1e-04
centrosome cycle	5	17.4×	1e-03
intermediate filament organization	6	14.9×	4e-04
epithelial cell differentiation	6	10.9×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

86 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1584 predictions. Top by Δscore:

Variant	Effect	Δscore
1:32180504:G:GT	donor_gain	1.0000
1:32181554:A:T	donor_gain	1.0000
1:32181571:GGTT:G	donor_gain	1.0000
1:32184601:G:GT	donor_gain	1.0000
1:32184604:G:GG	donor_gain	1.0000
1:32187945:T:TA	acceptor_gain	1.0000
1:32187950:CCAG:C	acceptor_loss	1.0000
1:32187952:A:AG	acceptor_gain	1.0000
1:32187952:AGCT:A	acceptor_gain	1.0000
1:32187952:AGCTG:A	acceptor_gain	1.0000
1:32187953:G:GT	acceptor_gain	1.0000
1:32187953:GC:G	acceptor_gain	1.0000
1:32187953:GCT:G	acceptor_gain	1.0000
1:32187953:GCTG:G	acceptor_gain	1.0000
1:32187953:GCTGG:G	acceptor_gain	1.0000
1:32188126:T:C	donor_loss	1.0000
1:32190246:GGAG:G	donor_gain	1.0000
1:32190247:G:GT	donor_gain	1.0000
1:32190250:GTA:G	donor_loss	1.0000
1:32192303:T:TA	acceptor_gain	1.0000
1:32192309:A:AG	acceptor_gain	1.0000
1:32192309:A:T	acceptor_loss	1.0000
1:32192310:G:GC	acceptor_gain	1.0000
1:32192310:GC:G	acceptor_gain	1.0000
1:32192310:GCA:G	acceptor_gain	1.0000
1:32192310:GCAT:G	acceptor_gain	1.0000
1:32192310:GCATA:G	acceptor_gain	1.0000
1:32192395:G:GT	donor_gain	1.0000
1:32192418:G:GT	donor_gain	1.0000
1:32192421:G:GT	donor_gain	1.0000

AlphaMissense

3598 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:32181308:T:C	L79P	1.000
1:32184543:T:C	L175P	1.000
1:32184594:T:C	L192P	1.000
1:32184615:T:C	L199P	1.000
1:32188036:T:C	L227P	1.000
1:32188056:G:C	A234P	1.000
1:32188069:G:C	R238P	1.000
1:32188078:T:A	L241H	1.000
1:32188078:T:C	L241P	1.000
1:32188087:T:C	L244P	1.000
1:32188092:C:A	R246S	1.000
1:32188093:G:C	R246P	1.000
1:32188099:T:C	L248P	1.000
1:32188105:G:C	R250P	1.000
1:32190095:G:C	R270P	1.000
1:32190115:T:C	F277L	1.000
1:32190116:T:C	F277S	1.000
1:32190116:T:G	F277C	1.000
1:32190117:C:A	F277L	1.000
1:32190117:C:G	F277L	1.000
1:32190128:T:A	L281Q	1.000
1:32190128:T:C	L281P	1.000
1:32190137:T:A	I284N	1.000
1:32190137:T:G	I284S	1.000
1:32190146:A:C	Q287P	1.000
1:32190179:T:C	L298P	1.000
1:32190192:C:A	N302K	1.000
1:32190192:C:G	N302K	1.000
1:32190200:T:C	L305P	1.000
1:32190202:G:C	A306P	1.000

dbSNP variants (sampled 300 via entrez): RS1000056294 (1:32186268 G>A,T), RS1000089966 (1:32185830 C>G,T), RS1000119851 (1:32190702 A>G), RS1000374182 (1:32197781 T>C), RS1000464886 (1:32183782 G>C), RS1000484779 (1:32198342 C>G,T), RS1000492288 (1:32179202 T>A), RS1000545665 (1:32178867 C>A,G,T), RS1000911177 (1:32179637 C>T), RS1001005750 (1:32197477 C>T), RS1001364939 (1:32179837 C>T), RS1001574640 (1:32191900 T>C), RS1001912226 (1:32193793 G>T), RS1002125984 (1:32194111 G>A), RS1002166786 (1:32184918 C>T)

Disease associations

OMIM: gene MIM:608676 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066423 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.45	Kd	3539	nM	CHEMBL5653589
5.45	ED50	3539	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149690: Binding affinity to human TXLNA incubated for 45 mins by Kinobead based pull down assay	kd	3.5386	uM

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
Valproic Acid	affects expression, decreases expression	2
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
perfluorooctanoic acid	decreases expression	1
coumarin	increases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
picoxystrobin	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Benztropine	decreases expression	1
Caffeine	decreases phosphorylation	1
Catechin	affects cotreatment, decreases expression	1
Cisplatin	increases expression	1
Cuprizone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ethyl Methanesulfonate	increases expression	1
Haloperidol	decreases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652732	Binding	Binding affinity to human TXLNA incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2K0	Abcam HeLa TXLNA KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.